de Ligt, K. M.
de Rooij, B. H.
Hedayati, E.
Karsten, M. M.
Smaardijk, V. R.
Velting, M.
Saunders, C.
Travado, L.
Cardoso, F.
Lopez, E.
Carney, N.
Wengström, Y.
Ives, A.
Velikova, G.
Sousa Fialho, M. D. L.
Seidler, Y.
Stamm, T. A.
Koppert, L. B.
van de Poll-Franse, L. V.
,
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (945345-2)
Article History
Received: 12 July 2022
Accepted: 30 November 2022
First Online: 20 January 2023
Declarations
:
: G Velikova: Personal Fees from Roche, Eisai, Novartis, Seattle Genetics, Sanofi; Grants from Breast Cancer Now, EORTC, Yorkshire Cancer Research, Pfizer, IQVIA (all outside the submitted work). F Cardoso: Consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime (all outside the submitted work). T Stamm: grants and personal fees from AbbVie, Roche, Sanofi, Takeda, and Novartis (all outside the submitted work). M Karsten: received speaker honorary from Roche and Astra Zeneca, no relationships or activities potentially influencing the submitted work. L Travado: member of the ECIBC expert group (European Commission Initiative on Breast Cancer), and member of the ABC Global Alliance. N Carney: is an employee and shareholder of F.Hoffmann-La Roche Ltd. BH de Rooij, E Hedayati, VR Smaardijk, N Carney, Y Seidler, TA Stamm, LB Koppert, LV van de Poll-Franse, are members of the H2O Health Outcomes Observatory (H2O). The other authors (KL, AI, CS, YS, YW, EH) declare they have no conflict of interest to report.
: All participants gave electronic informed consent for participating in the Delphi.
: The Netherlands Cancer Institute Institutional Review Board (IRB) declared that formal approval from an ethics committee was not required. Local execution was approved under registration number IRBd21-148.